Wisconsin Opioid Project ECHO (Extension for Community Healthcare Outcomes)

Wisconsin Opioid Project ECHO 2018-11-29T08:00:44+00:00

ECHO - Extension for Community Healthcare OutcomesWhat is Project ECHO®?

Project ECHO® (Extension for Community Healthcare Outcomes) is a statewide educational, teleECHO initiative that connects clinical experts with primary care providers and medication assisted treatment prescribers across Wisconsin in an effort to reduce opioid-related complications. Via a regularly scheduled videoconference, a multidisciplinary panel of specialists provide education and lead a collaborative discussion on submitted patient cases.

This effort is sponsored by UW Department of Family Medicine and Community Health and the Wisconsin Department of Health Services, Division of Care and Treatment Services.

Interested in Joining?

Tune in the third Friday of each month from 12:30 p.m. to 1:30 p.m. for our clinic sessions.

Clinic sessions will focus on opioid use disorders, management, and treatment strategies.

CE credit is available to those who attend the live teleconference.

Sign up to receive email notifications about Wisconsin Opioid Project ECHO clinic sessions.

Continuing Education Information

Accreditation Statement

Accreditation

In support of improving patient care, this activity has been planned and implemented by the University of Wisconsin–Madison ICEP and the Wisconsin Department of Health Services, Division of Care and Treatment Services. The University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statement

Accreditation Council for Pharmacy Education (ACPE)

The University of Wisconsin-Madison ICEP designates this live activity for a maximum of 1 hour of knowledge-based CE credit. Credit can be earned by successfully completing this live activity. Pharmacists and Pharmacy Technicians should claim only the credit commensurate with the extent of their participation in the activity. CE credit information, based on verification of live attendance, will be provided to NABP within 60 days after the activity completion.

Pharmacists and Pharmacy Technicians must enter their NABP number in their profile in order to receive credit.

2018 Universal Activity Number (UAN)
JA0000358-9999-18-095-L04-P
JA0000358-9999-18-095-L04-T

2019 Universal Activity Number (UAN)
JA0000358-9999-19-002-L04-P
JA0000358-9999-19-002-L04-T

American Medical Association (AMA)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 ANCC contact hour.

The University of Wisconsin–Madison School of Nursing is Iowa Board of Nursing provider 350.

For more Continuing Education information visit:
https://ce.icep.wisc.edu/wiopioidprojectecho-fy19-20/node/3195

Funding

Funding for this project was made possible by grant 1H79T1080247-01 from the Substance Abuse and Mental Health Services Administration. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official polices of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Policy on Faculty and Sponsor Disclosure

It is the policy of the University of Wisconsin–Madison ICEP, that the faculty, authors, planners, and other persons who may influence content of this CE activity disclose all relevant financial relationships with commercial interests in order to allow CE staff to identify and resolve any potential conflicts of interest.  Faculty must also disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation(s).

Detailed disclosures will be available prior to the start of the activity.